BPC-157
peptideevidence: emerging · v1.0.0Description
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models. Lyophilized powder. Reconstitute with bacteriostatic water for in-vitro research. Store at -20°C. Certificate of Analysis attached to this listing.
Mechanism summary
Potential effects on angiogenesis, tissue signaling, and repair pathways.
How it works
BPC-157, or Body Protection Compound 157, is a synthetic peptide that has been studied primarily for its potential in promoting healing and tissue repair. The mechanism of action involves several key pathways, notably the activation of the vascular endothelial growth factor receptor 2 (VEGFR2), which plays a crucial role in angiogenesis—the formation of new blood vessels. This is particularly significant in the context of injury recovery, as enhanced blood flow can facilitate the delivery of nutrients and oxygen to damaged tissues.
In addition to VEGFR2 activation, BPC-157 has been shown to influence nitric oxide (NO) signaling pathways. Nitric oxide is a critical mediator in various physiological processes, including vasodilation and blood flow regulation. Studies have indicated that BPC-157 can enhance endothelial nitric oxide synthase (eNOS) activity, leading to increased NO production. This effect may contribute to improved vascular function and tissue repair mechanisms.
Research has demonstrated that BPC-157 can positively affect tendon cell behavior in cultured cells and rodent models, promoting cell proliferation and migration, which are essential for effective tissue regeneration. For instance, Chang et al. (Journal of Applied Physiology, 2011) and subsequent studies by Hsieh et al. (2017, 2020) have explored these cellular effects, providing a foundation for understanding how BPC-157 may aid in recovery from injuries.
Despite the promising preclinical evidence, it is important to note that the majority of research has been conducted in animal models, and human data remains limited. A systematic review by Vasireddi et al. (HSS Journal, 2025) concluded that while the biological mechanisms are well-documented, the clinical evidence in humans is insufficient to support definitive therapeutic recommendations. Therefore, while BPC-157 shows potential in enhancing healing processes, further research, particularly in human trials, is necessary to fully elucidate its efficacy and safety profile. [Source: Peptide Dosing Protocols]
In plain language
BPC-157 works by promoting healing through mechanisms that enhance blood vessel formation and improve blood flow, which helps repair tissues.
Reference details
Route(s)
subcutaneous, oral
Tags
gut, repair, vascular
Active
yes
Product details · BC20
Price
$79.99
Stock
out of stock
Mol. weight
1419.5 g/mol
Formula
C62H98N16O22
Purity
≥ 99%
CAS #
137525-51-0
Amino sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
COA: View certificate (batch TET-5812-a) →
Teton Labs product catalog · research-use compound data.
💉 Dosing — 3 references (verbatim from source · not a recommendation)
Dose
250-500 mcg once or twice daily
Route
subcutaneous
Frequency
once or twice daily
Duration
4-8 weeks
Cycle
4-8 week cycles, may repeat after a break
Reconstitution
Reconstitute lyophilized powder with bacteriostatic water; refrigerate after mixing
Vial
Commonly supplied as 5 mg or 10 mg vials
Source: Practitioner Peptide Dosing Reference (commonly published ranges) — Compiled practitioner reference (internal_protocol)Source-backedProvider-reviewed
Dose
250-500 mcg
Route
subcutaneous or oral or topical
Frequency
Twice daily (morning and evening)
Duration
4-6 weeks
Reconstitution
Bacteriostatic water
Source: Peptide Protocol Wiki (peptideprotocolwiki.com) (publication)Source-backedProvider-reviewed
Dose
Standard: 250 mcg twice daily · Low: 250 mcg once daily · High: 500 mcg twice daily
Route
Subcutaneous injection
Frequency
Twice daily
Duration
4-6 weeks
Cycle
Standard
Reconstitution
2 mL BAC water
Source: Peptide Dosing Protocols (peptidedosingprotocols.com) (publication)Source-backedProvider-reviewed
Safety, contraindications & monitoring
Contraindications — who should avoid
- Not FDA-approved as of June 2026.
Safety & side effects
- No adverse effects reported in a 2025 IV pilot in two adults.
Monitoring & bloodwork
- CBC at baseline and week 4
Clinical evidence
- BPC-157 activates FAK-paxillin complexes and JAK-2 signaling. · Sikiric et al., Current Neuropharmacology, 2016
- BPC-157 has no published human Phase 2 or Phase 3 dose-finding trial.
- BPC-157 remains stable in human gastric juice for more than 24 hours. · Sikiric et al., Current Pharmaceutical Design, 2011
- BPC-157 has been reported to upregulate VEGFR2 and activate the Akt-eNOS pathway. · Hsieh et al., Journal of Molecular Medicine, 2017
Source-backedProvider-reviewedApproved findings drawn from your sources — decision support, not medical advice.
Provider-only reference. This page does not constitute medical advice, a recommendation, or dosing guidance.